4
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Minoxidil and Its Use in Hair Disorders: A Review [Corrigendum]

      Drug Design, Development and Therapy

      Dove

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Suchonwanit P, Thammarucha S, Leerunyakul K. Drug Des Devel Ther. 2019;13:2777–2786. On page 2781, Androgenetic alopecia section, last paragraph, “A combination of low-dose minoxidil 2.5 mg and spironolactone 25 mg in patients with FPHL showed preferable outcomes with decrease hair shedding and improved hair density. The mean severity score reduced to 2.3 at 6 months and 2.6 at 12 months. Mild adverse effects including urticaria, postural hypotension, and facial hypertrichosis were reported.” should read “A combination of low-dose minoxidil 0.25 mg and spironolactone 25 mg in patients with FPHL showed preferable outcomes with decrease hair shedding and improved hair density. Mean reduction in hair shedding score was 2.3 at 6 months and 2.6 at 12 months. Mild adverse effects including urticaria, postural hypotension, and facial hypertrichosis were reported.” Following feedback from a reader, we found 1) the incorrect dosage was listed for minoxidil and 2) the reduction in severity score relates to the visual-analogue Sinclair hair shedding scale. The authors apologize for these errors.

          Related collections

          Author and article information

          Journal
          Drug Des Devel Ther
          Drug Des Devel Ther
          DDDT
          dddt
          Drug Design, Development and Therapy
          Dove
          1177-8881
          10 February 2020
          2020
          10 February 2020
          : 14
          : 575
          Article
          247601
          10.2147/DDDT.S247601
          7021914
          © 2020 Suchonwanit et al.

          This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php).

          Page count
          Pages: 1
          Categories
          Corrigendum

          Pharmacology & Pharmaceutical medicine

          Comments

          Comment on this article